Look­ing to bol­ster im­mune check­point R&D, Gilead buys Miro­Bio as it takes next-gen check­point ther­a­py to the clin­ic

While Gilead dropped dis­ap­point­ing da­ta on its Ar­cus-part­nered CD37 in­hibitor Wednes­day af­ter­noon, the bio­phar­ma is mak­ing moves to cush­ion its im­mune check­point pipeline.

For $405 mil­lion, Gilead will buy Miro­Bio, an Ox­ford spin­out which just a month ago an­nounced its £80 mil­lion Se­ries B round. Miro­Bio chair Eliot Charles had told End­points News then that the biotech was look­ing for a new CEO, but it ap­pears it won’t need to do that any­more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER